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Introduction
The repetitive jaw-muscle activity generally known as bruxism (clenching and grinding of 
teeth during both sleep and while awake) (1) is commonly encountered by clinicians in 
dentistry, neurology, and psychiatry. Sleep bruxism (SB) has been reclassified in recent 
years as a sleep-related movement disorder; this category also includes periodic limb 
movement and rhythmic movement disorders (2). SB has been estimated at 10-20% of the 
pediatric population, 5-8% of the adult population, with a decrease to 3% in geriatric 
populations; no sex differences have been documented to date (3-5). SB is more frequent in 
smokers, those with high consumption of caffeine or alcohol, and in individuals taking 
neuroactive chemicals that affect the CNS (6-10). Clenching and grinding of teeth activities 
are often seen in individuals with stress and anxiety disorders (11-13) and are comorbid with 
restless leg syndrome, sleep apnea, oromandibular myoclonus, rapid eye movement behavior 
disorder, and other parasomnias (10, 14). Iatrogenic secondary causes of such activities may 
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include delivery/cessation of neuroactive medications (15), certain dental procedures, and 
treatment for temporomandibular disorder (TMD) (16-18). A high occurrence of TMD pain 
has been documented in persons exhibiting (1) the behaviors of both SB and daytime 
clenching (awake bruxism), and (2) the sleep disorders of sleep apnea, insomnia, and 
bruxism (10, 15, 19-24).
A link between emotion-induced brux-like activities and group I temporomandibular 
disorder (TMD) was proposed long ago (25-27), although the mechanism underpinning this 
association is still unclear. Recent neuroimaging studies of bruxism have identified the 
involvement of the Hypothalamic–Pituitary–Adrenal (HPA) axis system, which is also 
implicated in TMD and Post-Traumatic Stress Disorder (PTSD). Currently, it is thought that 
bruxism, PTSD, and other stress-related psychiatric disorders, are due to a dysfunction of a 
circuit involving the medial prefrontal/anterior cingulate cortical region, dorsolateral 
prefrontal cortex (DLPFC), hippocampus, and amygdala.
The role of neurochemicals in anxiety-related behaviors such as bruxism has been and 
continues to be of intense interest for some time now (9, 28-34). The exact neurochemical 
mechanisms that cause certain selective serotonin reuptake inhibitors (SSRIs) to manifest 
sleep bruxism is a focus of research efforts (9, 31, 33) as are those involved in the important 
comorbid factors of sleep regulation, endocrine systems, autonomic functions, stress/
anxiety, and motor control (14, 15, 35-37). As demonstrated by the bruxism-ameliorating 
effects of the drugs gabapentin, tiagabine, gamma-hydroxybutyrate, diazepam, and 
lorazepam, the major neurotransmitter γ-aminobutyric acid (GABA) is suggested to play a 
critical role in bruxism (9).
Magnetic resonance spectroscopy (MRS) techniques allow for a noninvasive examination of 
in vivo brain function by assessing regional concentrations of neurotransmitter metabolites 
(38). As determined by recent MRS studies (39, 40), GABA plays an important role in the 
pathophysiology of human anxiety disorders such as panic disorder and PTSD (41). 
Goddard et al. discovered lower than normal cortical GABA levels in panic disorder 
individuals (42, 43). The etiology of oral dysfunctions such as bruxism and TMD is 
multifactorial and psychological factors are considered a major component in the initiation 
and progression of these disorders (21), which suggests that GABA neuronal system may 
also be critical in the manifestation of bruxism. The increased incidence of anxiety and 
depression in these patients (26, 44-46) has led to a theory that psychological factors, such 
as anxiety, predispose patients to TMD/bruxism by increasing tooth grinding and clenching 
behaviors, which may produce masticatory muscle fatigue and soreness (25-27). We 
hypothesized that the stress-related behavioral disorder of bruxism and anxiety-related 
disorders share similar underlying mechanisms involving the inhibitory neurotransmitter 
GABA as well as the metabolites N-acetylaspartate (NAA), creatine, choline-containing 
compounds, myo-inositol, glutamate and glutamine (47). To study this cross-link between 
brux-like behaviors and anxiety-related disorders, we performed a proton (1H) MRS study 
for metabolite quantification in anxiety-related regions of the brain involved in the HPA axis 
system. HPA axis dysfunction plays a major role in the anxiety disorders reported by 
patients who clench and grind their teeth and suffer with TMDs (48). We focused on two 
HPA-axis brain regions, the right hippocampus and right thalamus and selected the right 
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hemisphere because of the documented laterality in stress-regulatory components of the 
HPA axis. In addition, we also investigated the DLPFC because of its role in anxiety-related 
disorders (49) and a dorsal anterior cingulate cortex/pre-supplementary motor area (dACC/
preSMA) involved in motor planning (50, 51). The dACC has also been implicated in 
anxiety behavioral disorders such as PTSD (52, 53) .
In this study we sought to identify parallels in metabolic and neurotransmitter changes 
between the manifestation of brux-like behavior and reported changes in anxiety disorders. 
The long term goal of this imaging-based, noninvasive research of the neurochemical 
mechanisms affecting the manifestation of oral behaviors such as bruxism is to provide 
improved treatment strategies in the clinical population.
Materials and Methods
Subject Recruitment
Subject group classification (see Appendix A) was based on an interview that was conducted 
after self-reported tooth clenching and grinding history, followed up by evaluation of each 
subject's protective occlusal splint and positive responses on the TMD history questionnaire 
(54). Examination of subjects’ occlusal splint confirmed that subjects indicating a history of 
possible brux-like behavior did in fact have an occlusal splint, which they were currently 
using and which was prescribed by a dentist specifically for the purpose of protecting the 
dentition from possible brux-like behaviors. The TMD questionnaire documented subjects’ 
perception of pain, loss of function, and possible brux-like behavior. Responses to the 
questions that best assessed possible brux-like behavior are presented in Appendix A, which 
shows not only the responses of both occlusal splint (OCS) and control (CON) subjects to 
selected questionnaire items, but also their occlusal splint use as prescribed and fabricated 
by dental clinicians. Based on this classification, 8 male subjects (age: 28.6±3.0 years; mean 
± SD) were recruited and classified in the OCS group. Subjects were classified to exhibit 
possible brux-like behavior if currently reporting active clenching and grinding of teeth and 
wearing of a protective occlusal splint, being right-handed, 20-45 years old, not currently 
under medication for migraine headaches, without previous history of brain injury or 
psychiatric problems, magnetic surgical implants, false teeth, retainers, or magnetic braces, 
having normal hearing sensitivity by self-report, and not being claustrophobic by self-report. 
The control (CON) group consisted of 9 age-matched (25.5±1.9 years) healthy men with the 
inclusion criteria identical to the OCS group except for possible brux-like behavior and 
occlusal splint use. In this study, the diagnosis of sleep bruxism was deemed “possible” 
because of OCS subject self-report and questionnaire use (1). Written informed consent 
approved by the Indiana University Institutional Review Board was obtained from all 
subjects prior to participation and all procedures conformed to international STROBE 
guidelines.
MRS data acquisition and analysis
1H MRS data were acquired on a 3 T Siemens Magnetom Tim-Trio MR scanner (Siemens 
Healthcare, Erlangen, Germany) using a 32-channel head array coil. Both single voxel short 
echo time Point RESolved Spectroscopy (PRESS) spectra (TE=30 ms, TR=1500 ms, 128 
Dharmadhikari et al. Page 3
Arch Oral Biol. Author manuscript; available in PMC 2015 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
averages) and GABA-edited spectra (TR=1500 ms, TE=68 ms) using MEGA-PRESS 
(55-57) were obtained from four volumes of interest (VOIs): thalamus (25×25×25 mm3, 392 
averages), hippocampus (17×40×17 mm3, 512 averages), DLPFC (25×30×22 mm3, 392 
averages) and dACC/preSMA (25×35×25 mm3, 392 averages). A reference spectrum 
without water suppression was obtained in each brain region for phase and frequency 
correction. Placements of the VOIs and representative spectra from each brain region are 
illustrated by Figure 1.
The post-processing and quantification of all spectra was performed with LCModel 
(v6.2-0R) (58). PRESS spectra were analyzed for the major metabolites N-acetyl aspartate 
(NAA), choline (Cho), total creatine (tCr), myo-inositol (mIns) and glutamate (Glu), 
whereas GABA levels were obtained from the GABA-edited spectra. Quantification results 
are expressed in institutional units (i.u.) and only the NAA, tCr, Glu, and mIns metabolites 
from the PRESS spectrum with LCModel fitting standard deviation below 20% were used 
for further statistical analysis. Since the GABA resonance at 3.0 ppm also contains some 
signal from macromolecules, GABA results are reported as GABA+ (GABA + 
macromolecules). More detailed descriptions of the MRS data acquisition and analysis 
methods are provided in Appendix B.
Statistical Analysis
All statistical calculations were performed with SPSS (Version 20.0, IBM Corp.). The 
questionnaire data were grouped into three categories: depression, anxiety and pain with an 
overall (summed) score calculated for each category. The scores in each category were 
compared between groups using the Wilcoxon–Mann–Whitney two-sample rank-sum test. 
Spearman's rank correlations were computed for the questionnaire scores in each of the 
categories and regional metabolite estimates. A Group (2; OCS and CON) × Region (4; 
hippocampus, DLPFC, thalamus and preSMA) × Metabolite (5; NAA, Glu, mIns, tCr, and 
GABA+) repeated measures ANOVA was performed with a post-hoc ANOVA F-test 
conducted where effects of Group × Region interaction were significant. In addition, 
questionnaire scores were examined in the regression analysis or as covariates when 
showing significant effects of Group.
Results
TMD questionnaire
As shown in Appendix A, questionnaire data from both groups indicated that all occlusal 
splint subjects reported experiencing daytime and night time tooth clenching/grinding, 
morning jaw soreness /stiffness, and the use of a protective occlusal splint obtained from a 
dentist. Control subjects had negative responses to all of the aforementioned questionnaire 
items shown in Appendix A.
Anxiety and depression scores in all subjects were significantly correlated (Spearman's r= 
0.736, p<0.01, two-sided). There were no significant group differences in the scores of 
depression (Mann-Whitney U=29, p=0.54, two-tailed) or pain (Mann-Whitney U=24.5, 
p=0.28, two-tailed), while a trend was present for anxiety (Mann-Whitney U=18.5, OCS 
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mean=3.88, CON mean=1.00, p=0.09, two-tailed). This trend-level anxiety score difference 
was in the anticipated direction (e.g. higher for the OCS). Therefore, anxiety scores were 
added as a covariate in the MRS data analysis to test whether anxiety contributed to the 
metabolite group differences reported below.
MRS
The multivariate tests in the repeated-measures ANOVA showed significant Group × 
Region interaction (Wilk's lambda=0.38, F=3.36). In the repeated-measures ANOVA, 
Group × Region interaction was significant for two metabolites, GABA+ (F(3,55)=6.66, 
p=0.001) and Glu (F(3,55)=3.22, p=0.031). Between-group post-hoc ANOVA showed 
significant effects only in the DLPFC, where lower levels of GABA+ (F(1,12)=14.01, 
p=0.003) and higher levels of Glu (F(1,13)=14.71, p=0.002) were observed in OCS. These 
GABA+ and Glu group differences in the DLPFC were reduced but remained significant 
(GABA+, F(1,13)=5.17,p=0.049; Glu; F(1,13)=5.829, p=0.039) after the inclusion of 
anxiety as a covariate. Furthermore, GABA+ and Glu levels in the DLPFC showed a 
significant negative relationship (Pearson's r=−0.754, p=0.003 two-sided) as illustrated by 
Figure 2. While no group differences in GABA+ and Glu were present in the hippocampus, 
these two metabolites did show positive relationship (Pearson's r=0.783, p=0.004 two-sided; 
see Figure 3).
Discussion
While the focus of previous neurochemical studies was on sleep bruxism (SB) (15), there is 
some evidence that the variability of bruxism symptoms in both diurnal and nocturnal forms 
may have a neurochemical basis, involving different brain regions such as the ventral 
tegmental area and the distribution of striatal dopaminoceptor-2 (D2R) receptors (59). In this 
study, lower GABA+ levels in occlusal splint DLPFC subjects suggest that anxiety-related 
circuits (49, 60) that may affect possible bruxism were less inhibited than in controls (Table 
1). Decreased frontal lobe GABA levels have also been detected in panic disorder 
individuals (42) albeit in the medial rather than dorsolateral prefrontal cortex.
A review of earlier studies of DLPFC metabolite levels in anxiety subjects indicates that the 
DLPFC plays an important role in responses to threatening stimuli, particularly in anxiety 
disorders (60-63). It is currently thought that the DLPFC guides control of tasks by 
providing excitatory feedback to pools of neurons that process task-relevant aspects of 
anxiety-provoking stimuli; in this case the DLPFC may enhance the manifestation of 
bruxism by channeling anxiety-associated stimuli to those brain regions actually causing the 
behavior. Increased DLPFC activity during an emotional Stroop task suggests that the 
DLPFC is important for task control mechanisms in the face of emotional distraction 
(64-66). The documented decrease of bruxism with increased age may also be related to an 
age-related decrease of DLPFC mechanisms regarding early perceptual features (67).
Hippocampus metabolite levels in anxiety subjects have been reported to show higher Glx, 
myo-inositol, and Cr, and to be correlated with psychiatric symptoms and mitochondrial 
disorders (68). Alterations in hippocampal activity and volume have also been documented 
in anxiety disorders (52, 69). In our study, no significant group differences were found for 
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any of the reported metabolites in the hippocampus. However, a significant positive 
correlation between GABA+ and Glu emerged. Interestingly, these two metabolites were 
negatively related in the DLPFC, which may reflect the documented bidirectional 
interactions between the hippocampus and the DLPFC (70). In this sense, our finding might 
indicate the presence of a negative feedback circuit between hippocampus and DLPFC, 
which may play an important role in regulating the manifestation of bruxing behaviors 
(71-73). The activity dynamics between the DLPFC and hippocampus in retrieval of facts 
during problem solving (70) and our findings may also suggest a role for both the DLPFC 
and hippocampus in motor memory systems (74, 75) that might be involved in bruxism 
behaviors. It has also been suggested that epileptic seizures involving limbic structures 
within the temporal lobe (hippocampus) may activate masticatory central pattern generators 
that help cause bruxism behaviors (76). A recent case report documented a 5-year old male 
with a cystic lesion compressing the left hippocampus and exhibiting teeth grinding 
behavior during sleep (77). It has been found that DLPFC of idiopathic generalized epilepsy 
patients demonstrate increased levels of glutamine and GABA compared with controls (57). 
This differs from our study in that DLPFC of OCS subjects showed significantly lower 
levels of GABA+ and higher levels of Glu (see Table 1). The precise neurochemical 
mechanisms and interactive relationships between epilepsy and brux behaviors need to be 
investigated further.
Thalamus metabolite levels in restless legs syndrome individuals demonstrate significantly 
higher levels of Glx/Cr than control subjects (78). In the present study, the thalamic GABA 
showed only trend-level group differences (see Table 1) that might be suggestive of another 
nondopaminergic neurologic system that plays a role in the manifestation of bruxism. It has 
also been noted that thalamus activity is decreased in PTSD, an important anxiety disorder 
(79-81).
In this study, we detected no metabolic group differences in the preSMA/dACC; this despite 
our earlier fMRI findings that the preSMA/dACC may play an important role in oral brux-
like behaviors such as tooth grinding and clenching (50, 51). This discrepancy may be due to 
the passive nature of the MRS scans in the present study, while our earlier fMRI studies 
employed the active, physical tasks of jaw clenching and tooth grinding.
Limitations of this study include: (1) modest sample size, and (2) occlusal splint wearer 
inclusion criteria that were based on self-report and were non-specific in bruxing 
classification. In addition, continuing analysis of possible sleep bruxism and pain data in the 
occlusal splint wearers was not performed. In this study, subject gender selection was 
necessarily driven by a small sample so we focused on males due to the higher incidence of 
PTSD and TBI in men (82, 83). In the future, we intend to include women subjects and 
make gender ratios similar and more representative of possible sleep bruxism behaviors 
prevalence. Polysomnography (PSG), the current gold standard for determination of bruxism 
(15, 84) was not used in this study because of limited research monies available to us. We 
hope to include PSG analyses in future studies.
Larger voxel sizes were chosen to compensate for the low signal-to-noise ratio of GABA 
MRS. The geometric limitations of the MRS VOIs preclude complete sampling of some 
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neuroanatomical regions or include small contributions of adjacent non-targeted regions. 
The measured GABA levels include some contribution from co-edited macromolecules 
(MM30) at 3 ppm and a small contribution from homocarnosine and are hence reported as 
GABA+ (GABA+MM30). However, changes in macromolecules have not been reported for 
anxiety-related disorders to date.
Conclusions
These results in our proof-of-concept study are the first indications of the disturbances in 
GABAergic and glutamatergic systems of possible sleep bruxers. Future research in larger 
samples should improve sensitivity of quantifying GABA and other pertinent metabolites 
and detecting group differences. In addition, results of this study indicate a need for a more 
comprehensive MRS investigation with an emphasis on the coupling of anxiety-related and 
limbic regions with executive control brain networks. The relevance of such research is 
supported by the observed differences between HPA anxiety-related brain areas as indicated 
by our finding of negative feedback between the hippocampus and DLPFC. Careful further 
investigations may reveal not only the neurochemical mechanisms underlying bruxism 
behaviors and their interactions with other anxiety disorders, but also myofascial TMD as 
recently documented by Gerstner et al. (85).
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Figure 1. 
Sagittal and axial views showing representative VOI placement in the thalamus, 
hippocampus, DLPFC and dACC/preSMA (left column) and the respective short TE single 
voxel 1H PRESS spectra (middle column) and MEGA-PRESS GABA spectra (right 
column). The GABA+ peak at 3 ppm is very prominent for all four regions of interest. VOI 
= Volume Of Interest.
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Figure 2. 
In the DLPFC, a significant negative correlation (Pearson coefficient=−0.754, p=0.003) is 
present between GABA+ and Glu concentrations.
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Figure 3. 
In the hippocampus, a significant positive correlation (Pearson coefficient=0.783, p=0.004) 
is present between GABA+ and Glu concentrations.
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Table 1
Metabolite concentrations (in i.u.) are listed for four brain regions and both groups.
Group Region NAA Glu mIns tCr GABA
CON
Hipp
Mean 3.83 4.64 4.62 3.66 2.32
Standard Deviation 0.70 0.60 1.02 0.75 0.20
N 7 7 7 7 7
DLPFC
Mean 5.20 4.15‡ 3.78 3.93 2.18‡
Standard Deviation 0.41 0.49 0.23 0.37 0.24
N 6 6 6 6 6
Thal
Mean 5.49 4.45 3.59 4.01 2.86*
Standard Deviation 0.77 1.03 0.86 0.62 0.36
N 7 6 7 7 7
dACC/preSMA
Mean 5.87 6.01 4.68 4.71 2.81
Standard Deviation 0.57 0.67 0.43 0.17 0.25
N 9 9 9 9 9
OCS
Hipp
Mean 3.96 4.46 3.40 3.21 2.40
Standard Deviation 0.94 0.60 0.79 0.92 0.32
N 6 5 6 6 8
DLPFC
Mean 5.21 4.97‡ 3.80 4.25 1.55‡
Standard Deviation 0.48 0.31 0.59 0.22 0.35
N 8 8 8 8 7
Thal
Mean 5.24 3.78 3.55 4.33 3.23*
Standard Deviation 0.48 0.60 0.48 0.36 0.38
N 8 8 8 8 8
dACC/preSMA
Mean 6.10 6.02 4.73 4.84 2.80
Standard Deviation 0.55 0.66 0.40 0.43 0.10
N 8 8 8 8 8
Significant (‡, p<0.01) or trend-level (*, 0.05 ≤ p ≤ 0.10) differences between occlusal splint-wearer (OCS) and control (CON) groups are 
indicated. Hipp = Hippocampus, DLPFC = Dorsolateral prefrontal cortex, Thal = Thalamus, dACC/preSMA = dorsal anterior cingulate cortex/pre-
supplementary motor area.
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